Chronic Phase Chronic Myeloid Leukemia

Also known as: Chronic phase chronic myeloid leukaemia / Leukemia, Myeloid, Chronic-Phase / Myeloid leukemia, chronic / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Chronic myeloid leukemia / CML / Chronic myelogenous leukaemia / Chronic myelocytic leukaemia / Leukemia myelocytic chronic / Chronic myelogenous leukemia / Leukaemia myelocytic chronic / Chronic granulocytic leukemia / Leukaemias chronic myeloid / Chronic myelocytic leukemia / Chronic granulocytic leukaemia / Chronic myeloid leukaemia / Myeloid leukaemia, chronic

DrugDrug NameDrug Description
DB08901PonatinibPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
DrugDrug NamePhaseStatusCount
DB04868Nilotinib1Active Not Recruiting1
DB08877Ruxolitinib1Active Not Recruiting1
DB04868Nilotinib1 / 2Recruiting1
DB08877Ruxolitinib1 / 2Recruiting1
DB01254Dasatinib2Active Not Recruiting2
DB00619Imatinib2Active Not Recruiting1
DB04868Nilotinib3Recruiting1
DB08901Ponatinib3Recruiting1
DB01254Dasatinib4Completed1